Background: Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy. Objective: We sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy. Methods: Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n 5 20) or 25 mg of rMal d 1 (n 5 20) or rBet v 1 (n 5 20) for 16 weeks. Adverse events were regularly recorded.
Abbreviations used
AE: Adverse events AIT: Allergen-specific immunotherapy BPE: Birch pollen extract BPRFA: Birch pollen-related food allergy DIAID: Division of Immunology, Allergy and Infectious Diseases OAS: Oral allergy syndrome SCT: Sublingual challenge test SLIT: Sublingual immunotherapy SPT: Skin prick test been described. [8] [9] [10] [11] [12] However, others have reported limited curative effects and in some cases even the onset of BPRFA during AIT. [13] [14] [15] [16] [17] [18] Previously, we found that sublingual immunotherapy (SLIT) with birch pollen (ie, applied directly at the site of food-induced allergic symptoms) improved birch pollinosis but did not ameliorate apple-induced OAS. 19 On the other hand, daily consumption of gradually increasing amounts of apple was able to induce a transient oral tolerance in 17 (63%) of 27 patients with apple allergy. 20 Beyond that, we observed immune responses indicative for peripheral tolerance development in patients with birch pollen allergy and apple allergy after sublingual administration of 50 mg of rMal d 1 on 2 consecutive days. 21 These promising findings inspired us to study the effects of SLIT with rMal d 1 on apple allergy and to compare them with those of rBet v 1.
We conducted a single-center, double-blind, placebocontrolled explorative study including 60 participants with birch pollen and apple allergy randomized to daily sublingual administration of placebo or 25 mg of rMal d 1 or rBet v 1 (n 5 20 for each group) for 16 weeks. Adverse events (AEs) were recorded regularly during the course of treatment. The efficacy on apple allergy was assessed with sublingual challenge tests (SCTs) with standardized doses of rMal d 1 before and after SLIT. 22 The participants also underwent skin prick tests (SPTs) with recombinant allergens, birch pollen extract (BPE), and fresh apple. Additionally, allergen-specific IgE and IgG 4 levels were monitored.
METHODS

Trial population
In 2012, we recruited 77 Austrian patients with birch pollen allergy aged 18 to 65 years who were reported to experience apple allergy. These subjects displayed rhinoconjunctivitis in the spring, positive SPT responses to BPE (ALK-Abell o, Hørsholm, Denmark) and fresh apple (a typical local cultivar, Pink Lady), and BPE-specific IgE levels of greater than 0.35 kU/L (ImmunoCAP; Thermo Fisher Scientific, Uppsala, Sweden). We excluded subjects who experienced symptoms to perennial allergens or had received birch pollen AIT within the past 5 years. After providing written informed consent, 72 subjects were screened for apple allergy by means of SCTs with rMal d 1 in December 2012 to January 2013. 22 Four subjects declined to participate. Sixty participants (31 female and 29 male participants; median age, 33 years; range, 20-64 years) who responded with OAS on SCTs to 1.6 to 25 mg of rMal d 1 were randomized 1:1:1 by using the ''randomizer for clinical trials 1.8.1'' (Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria; available at: https://www.randomizer.at/) to daily sublingual administration of rBet v 1 (25 mg/d), rMal d 1 (25 mg/d), or placebo (5 mmol/L phosphate buffer, pH 7.4, supplemented with 25% vol/vol glycerol), respectively (Fig 1) .
Trial design
This randomized, double-blind, placebo-controlled trial (ClinicalTrials. gov no. NCT01449786 and EudraCT no. 2011-001221-24) was conducted at the Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DIAID), Medical University of Vienna, Vienna, Austria, in accordance with Good Clinical Practice and the Declaration of Helsinki and with ethical clearance of the local ethics committee (EK228/2011). The treatment period of 16 weeks started in August 2013. The first administration of 300 mL of the study medication was performed at the DIAID. Participants were asked to keep the solution under their tongue for 1 to 2 minutes before swallowing. Each participant was monitored for the next 60 minutes, and any AEs were recorded. Subsequent doses were self-administered at home. Every 4 weeks, the subjects visited the DIAID to report AEs that occurred during the past 4 weeks. In addition, used glass flasks were exchanged for new ones containing the study medication for the following 4 weeks. The study was monitored by the Koordinationszentrum f€ ur Klinische Studien at the Medical University of Vienna, Vienna, Austria.
Investigational products
Bet v 1a-GMP-0802 (termed rBet v 1) and Mal d 1.0108-GMP-0902 (termed rMal d 1) were produced under good manufacturing practice conditions by Biomay AG (Vienna, Austria). For sublingual administration, each allergen (84 mg/mL) was dissolved in previously determined optimum buffers (rBet v 1 in 5 mmol/L phosphate buffer, pH 7.4, and rMal d 1 in 20 mmol/L carbonate buffer, pH 9.0), supplemented with 25% vol/vol glycerol, and kept in dark glass flasks at 48C. The concentration and integrity of both allergens under these conditions after storage at 48C for 6 months was tested by using the bicinchoninic acid assay (Sigma-Aldrich, Vienna, Austria), SDS-PAGE, ELISA, immunoblotting, and size exclusion chromatography (see Table E1 and Figs E1-E4 in this article's Online Repository at www.jacionline.org) and proved the stability of both study drugs.
SCTs
SCTs were performed with increasing doses of rMal d 1 (1.6, 3.13, 6.25, 12.5, 25, and 50 mg), as described previously. 22 Briefly, the challenge solution (75 mL of 0.9% wt/vol NaCl containing no or the indicated concentrations of rMal d 1) was pipetted directly under the tongue, and the participants were asked not to swallow for 2 minutes. The dose was increased every 20 minutes until relevant objective symptoms, such as erythema, blister formation, edema, and swelling of the lips, tongue, and larynx, occurred up to a maximum dosage of 50 mg rMal d 1. None of the subjects reacted to 0.9% wt/vol NaCl alone.
Skin testing
Skin tests were performed on the flexor aspect of the forearms with a standardized prick needle (prick test lancets; ALK-Abell o) with BPE (ALK-Abell o), fresh apple (Pink Lady), and titrated concentrations (1.6-50 mg/mL) of rMal d 1 and rBet v 1, as previously described. 23 Histamine and 0.9% wt/vol NaCl served as positive and negative controls, respectively. Reactions were recorded after 20 minutes. Wheal area was evaluated by using ImageJ software (Rasband W.S., National Institutes of Health, Bethesda, Md; http://imagej.nih.gov/ij/, 1997-2016). 
Efficacy assessments
The primary end point of efficacy was the change from baseline to the end of treatment (16 weeks 
Statistical analysis
This pilot study was explorative in nature. For the proportion of AEs in the 3 treatment groups at different time points, we computed 95% Clopper Pearson CIs. Longitudinal differences were tested with the Wilcoxon signed-rank test, except when indicated differently. Differences between the 3 treatment groups were tested with rank-based analysis of covariance by using ranks of baseline measurements as covariates. For pairwise comparisons of the groups, we applied Tukey post hoc tests. A P value of less than .05 was considered statistically significant. Statistical analysis was performed with SPSS 10.01 (IBM, Armonk, NY) and SAS 9.4 software (SAS Institute, Cary, NC).
RESULTS Subjects
Sixty participants with birch pollen-associated apple allergy, as determined by a positive SCT result with rMal d 1, were randomized into 3 groups of 20 subjects each to sublingually receive placebo, rMal d 1 (25 mg/d), or rBet v 1 (25 mg/d) for 16 weeks (Fig 1) . Table I shows participants' demographics and baseline characteristics for each group. All participants displayed IgE specific for BPE, rBet v 1, and rMal d 1. Two participants in the Bet v 1 group and 2 participants in the placebo group had negative results for IgE to apple extract. One participant in the placebo group and 1 participant receiving Bet v 1 withdrew voluntarily because of AEs (see Table E2 in this article's Online Repository at www.jacionline.org). Two participants in the Bet v 1 group withdrew voluntarily because of lack of time and moving away from Vienna, respectively. Taken together, 56 participants received the planned treatment (Fig 1) .
Safety analysis
No severe or systemic AEs were recorded during the entire course of the study (see Table E2 ). All AEs were considered to be treatment emergent by the blind investigator because the participants rated all symptoms, including headache, eye edema, and conjunctivitis, as similar to symptoms when eating an apple. All symptoms, including subjective reactions, were recorded to obtain a detailed comparison of AEs induced by rBet v 1 and rMal d 1 (see Table E2 ). After the first sublingual administration, 19 (95%) participants in each of the active groups and 11 (55%) participants in the placebo group reported at least 1 AE (see Table E2 ). To simplify monitoring of the progression of AEs during the course of the study, we summarized oral and ear pruritus, oral blisters, edema, and/or throat irritation as OAS. 
Efficacy analysis
Participants were sublingually challenged with increasing doses of rMal d 1 from December 2012 to January 2013 to exclude any possible effect of seasonal exposure to birch pollen. SCTs were repeated in the same time period after treatment (December 2013-January 2014). Doses of rMal d 1 inducing relevant oral symptoms at both time points were recorded for each subject. Overall, higher doses of rMal d 1 were needed after SLIT with rMal d 1 (P < .001, Fig 3) . In detail, 14 (70%) of 20 rMal d 1-treated participants responded to higher challenge doses after treatment. Notably, 5 (25%) of 20 participants tolerated the highest dose of rMal d 1 and a subsequent challenge with 20 g of fresh apple. Two (10%) patients had OAS to lower doses and 4 (20%) patients had OAS to the same dose of rMal d 1 after treatment. In contrast, no longitudinal differences in SCTs were found in the 16 rBet v 1-treated participants (Fig 3) . In detail, 7 (44%) of 16 participants improved their apple allergy. One (6%) of these subjects tolerated all doses of rMal d 1 and fresh apple. Six (38%) of 16 participants had OAS to lower doses, and 3 of (19%) 16 participants had OAS to the same dose of rMal d 1 after treatment. In the placebo group 8 (42%) of 19 Table E2 ) were summarized as OAS. Percentages of participants with OAS together with 95% Clopper Pearson CIs are shown.
participants improved and 5 (26%) worsened on SCTs. Six (32%) participants responded to the same dose of rMal d 1 before and after treatment. A significant difference of rMal d 1 doses required to induce OAS after treatment was demonstrated among the 3 groups in rank-based analysis of covariance (P 5 .0011, F test). The rMal d 1-treated group differed significantly from both the placebo and rBet v 1-treated groups (P 5 .001 and P 5 .038, respectively, Tukey post hoc tests). The rBet v 1-treated group did not differ from the placebo group.
Skin test reactivity
From December 2012 to January 2013, all 60 participants underwent SPTs with histamine, BPE, fresh apple, and titrated concentrations of recombinant allergens (see Fig E5 in this article's Online Repository at www.jacionline.org). For comparison of skin reactivity of the 56 participants before and after treatment, we chose concentrations of 25 mg/mL rBet v 1 and 50 mg/mL rMal d 1 because they induced wheal areas comparable with those induced by commercial BPE at baseline (see Fig E5) . SLIT with rMal d 1 led to a longitudinal decrease of wheal areas to rMal d 1 (P 5 .022), whereas skin reactivity to fresh apple, rBet v 1, BPE, and histamine did not change (Fig 4) . SLIT with rBet v 1 significantly decreased skin reactivity to rBet v 1 (P 5 .023) and BPE (P 5 .031, Fig 4) , whereas skin reactivity to rMal d 1 and fresh apple remained unchanged. In the placebo group no changes of wheal areas to any of the tested agents were observed.
Immune responses
IgE and IgG 4 levels specific for rBet v 1 and rMal d 1 were measured in sera collected at baseline and after treatment. SLIT with rMal d 1 induced rMal d 1-specific IgG 4 antibody (P < .001) but affected neither rBet v 1-specific IgE and IgG 4 levels nor rMal d 1-specific IgE levels (Fig 5) . In contrast, SLIT with rBet v 1 induced IgE and IgG 4 antibodies specific for both allergens. Except for Mal d 1-specific IgG 4 , these levels were significantly increased compared with those in participants who received rMal d 1 and placebo (Fig 5) . In the placebo group no remarkable changes of allergen-specific antibody levels before and after treatment were observed. The calculation of rMal d 1-specific IgG 4 /IgE ratios revealed a longitudinal increase in participants treated with rMal d 1 (P 5 .012), a decrease in participants treated with rBet v 1 (P 5 .049), and no change in the placebo group (Fig 5) .
DISCUSSION
One novelty of this pilot study is investigation of the safety, efficacy, and immune effects of a sublingually administered recombinant food allergen. A second innovation is the use of defined amounts of rMal d 1 for standardized assessment of food-induced clinical responses before and after treatment. Former studies have relied on prick-to-prick tests, food challenges, or both with fresh apples. However, these test methods cannot guarantee the use of constant amounts of Mal d 1 for challenges at different time points because apples content depends strongly on the cultivar, stage of maturation, and storage conditions. 24, 25 Moreover, Mal d 1 is easily destroyed during preparation of the test meals because this protein is extremely susceptible to acidic conditions and proteases. 26 Another important feature of this trial is the parallel analysis of all parameters induced by equal doses of rMal d 1 and rBet v 1, which, for the first time, allow direct comparison of SLIT with 2 homologous allergens, displaying 56% sequence identity (71% homology) and a common 3-dimensional fold. 27 Daily sublingual administration of 25 mg of rMal d 1 for 16 weeks was safe and induced an improvement in apple allergy compared with placebo. Notably, 70% of the participants showed an increased rMal d 1 threshold in SCTs, and 25% of the participants tolerated a cumulative amount of 98.8 mg of rMal d 1 plus 20 g of fresh apple after treatment. After 44 weeks of peanut SLIT, 70% of 20 subjects receiving peanut SLIT were responders compared with 15% of 20 subjects receiving placebo. 28 Commercialized SLIT with peach extract for 12 months enhanced the threshold of peach in food challenges in 92% of 23 subjects. 29 This clinical improvement was accompanied by a reduction of skin reactivity and enhanced Pru p 3-specific IgG 4 /IgE ratios. 29 SLIT with rMal d 1 also significantly reduced skin reactivity to rMal d 1 but not to rBet v 1 and a significant increase in rMal d 1-specific IgG 4 /IgE ratios. Transient tolerance to apple in patients with birch pollen-related apple allergy has been achieved by oral immunotherapy (ie, daily intake of increasing amounts of fresh apple for an average time interval of 20 weeks). 20 However, this desensitization with unknown doses of the major apple allergen was accompanied by neither improved skin reactivity nor enhanced allergen-specific IgG 4 levels and referred to the treatment-induced exhaustion of local mast cells. 20 We observed a clear alteration of the rMal d 1-specific immune response indicative of induction of immune tolerance. 30 In addition, 2 participants in the rMal d 1 group reported to be tolerant to apple 2 years after the treatment (data not shown). We conclude that administering a constant sublingual dose of the major apple allergen is necessary to effectively treat birch pollen-associated apple allergy. This conclusion is further supported by the notably different clinical and immunologic effects of SLIT with 25 mg of rBet v 1. Overall, these participants did not improve their sublingual reactivity to rMal d 1, although they experienced a similar extent of treatment-emergent OAS during the course of treatment Lines indicate median values. *P < .05, **P < .01, and ***P < .001, Wilcoxon signed-rank test. (Fig 2) . Thus, despite the exhaustion of sublingual mast cells by rBet v 1, no desensitization to the highly cross-reactive rMal d 1 was achieved. This limited improvement of the associated apple allergy matches our previous results with a yearlong SLIT treatment with BPE, demonstrating that apple allergy improved in 33%, worsened in 33%, and remained unaffected in 33% of the participants with improved birch pollinosis. 19 In another trial birch pollen SLIT improved apple allergy in only 1 of 11 subjects but induced food allergy in 3 of 11 subjects. 16 One of our rBet v 1-treated participants also tolerated the full SCT procedure with rMal d 1 and 20 g of fresh apple, indicating that a limited number of subjects might benefit from SLIT with the pollen allergen. Recently, daily sublingual administration of 25 mg of rBet v 1 in fast-dissolving tablets for 5 months has been reported to effectively improve birch pollinosis. 31 Our participants displayed significantly reduced skin reactivity to rBet v 1 and BPE, as well as enhanced rBet v 1-specific IgE and IgG 4 antibody responses. In parallel, rMal d 1-specific IgE and IgG 4 levels significantly increased during treatment. We assign this finding to the induction of cross-reactive rBet v 1-specific antibody. However, the ratio of rMal d 1-specific IgG 4 /IgE antibodies decreased during treatment.
In summary, we demonstrate that equal doses of 2 homologous and highly cross-reactive allergens administered directly at the site of food-induced allergic symptoms induce surprisingly different clinical and immunologic responses. Notably, SLIT with rBet v 1 showed limited clinical efficacy on BPRFA. Because allergic reactions to apple are one of the best studied examples of BPRFA, we conclude that BPRFA cannot be treated effectively with the primary sensitizer (ie, the major birch pollen allergen).
Previously, we demonstrated that rMal d 1 improves the sensitivity and specificity of in vitro and in vivo diagnosis of BPRFA in 21 patients with birch pollen allergy. 22, 23 This trial substantiates these findings in an additional 60 patients with birch pollen allergy and illustrates that the recombinant apple protein is very practical for SLIT. The vast majority of subjects considered the study drug to be easy to handle and neutral in taste (see Table E2 ). In contrast to its native and extremely labile counterpart, the recombinant major apple allergen proved to be biochemically and immunologically stable, which seems relevant for the success of treatment (see Table E1 and Figs E1-E4). In view of the relatively short treatment duration of 16 weeks and the small study population, the observed clinical and immunologic effects of SLIT with rMal d 1 are significant. In summary, daily sublingual administration of rMal d 1 is a promising approach for safe and effective treatment of birch pollen-associated apple allergy.
